These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 35207460)

  • 1. The Impact of 52-Week Single Inhaler Device Triple Therapy versus Dual Therapy on the Mortality of COPD Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Lai CC; Chen CH; Chen KH; Wang CY; Huang TM; Wang YH; Wang HC
    Life (Basel); 2022 Jan; 12(2):. PubMed ID: 35207460
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single-inhaler triple vs single-inhaler dual therapy in patients with chronic obstructive pulmonary disease: a meta-analysis of randomized control trials.
    Long H; Xu H; Janssens JP; Guo Y
    Respir Res; 2021 Jul; 22(1):209. PubMed ID: 34301267
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of single inhaler triple therapy vs single inhaler dual therapy or separate triple therapy for the management of chronic obstructive pulmonary disease: a systematic review and meta-analysis of randomized controlled trials.
    Lai CC; Chen CH; Lin CYH; Wang CY; Wang YH
    Int J Chron Obstruct Pulmon Dis; 2019; 14():1539-1548. PubMed ID: 31371939
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Versus Other Inhaled Corticosteroid/Long-Acting Muscarinic Antagonist/Long-Acting β
    Ferguson GT; Darken P; Ballal S; Siddiqui MK; Singh B; Attri S; Holmgren U; de Nigris E
    Adv Ther; 2020 Jun; 37(6):2956-2975. PubMed ID: 32335859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluating triple ICS/LABA/LAMA therapies for COPD patients: a network meta-analysis of ETHOS, KRONOS, IMPACT, and TRILOGY studies.
    Calzetta L; Ritondo BL; de Marco P; Cazzola M; Rogliani P
    Expert Rev Respir Med; 2021 Jan; 15(1):143-152. PubMed ID: 32856967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medium-dose ICS-containing FDCs reduce all-cause mortality in COPD patients: an in-depth analysis of dual and triple therapies.
    Calzetta L; Ritondo BL; Matera MG; Chetta A; Rogliani P
    Expert Rev Respir Med; 2022 Mar; 16(3):357-365. PubMed ID: 34196591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Triple versus LAMA/LABA combination therapy for patients with COPD: a systematic review and meta-analysis.
    Koarai A; Yamada M; Ichikawa T; Fujino N; Kawayama T; Sugiura H
    Respir Res; 2021 Jun; 22(1):183. PubMed ID: 34154582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis.
    Rodrigo GJ; Price D; Anzueto A; Singh D; Altman P; Bader G; Patalano F; Fogel R; Kostikas K
    Int J Chron Obstruct Pulmon Dis; 2017; 12():907-922. PubMed ID: 28360514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparisons of exacerbations and mortality among regular inhaled therapies for patients with stable chronic obstructive pulmonary disease: Systematic review and Bayesian network meta-analysis.
    Lee HW; Park J; Jo J; Jang EJ; Lee CH
    PLoS Med; 2019 Nov; 16(11):e1002958. PubMed ID: 31730642
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Triple versus dual inhaler therapy in moderate-to-severe COPD: A systematic review and meta-analysis of randomized controlled trials.
    Zayed Y; Barbarawi M; Kheiri B; Haykal T; Chahine A; Rashdan L; Hamid K; Sundus S; Banifadel M; Aburahma A; Bachuwa G; Chandran A
    Clin Respir J; 2019 Jul; 13(7):413-428. PubMed ID: 30947394
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adding a LAMA to ICS/LABA Therapy: A Meta-analysis of Triple Combination Therapy in COPD.
    Calzetta L; Cazzola M; Matera MG; Rogliani P
    Chest; 2019 Apr; 155(4):758-770. PubMed ID: 30660781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative cardiovascular safety of LABA/LAMA FDC versus LABA/ICS FDC in patients with chronic obstructive pulmonary disease: a population-based cohort study with a target trial emulation framework.
    Chen CY; Pan SW; Hsu CC; Liu JJ; Kumamaru H; Dong YH
    Respir Res; 2023 Sep; 24(1):239. PubMed ID: 37775734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Triple therapy
    Cazzola M; Rogliani P; Calzetta L; Matera MG
    Eur Respir J; 2018 Dec; 52(6):. PubMed ID: 30309975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Triple therapy (ICS/LABA/LAMA) in COPD: time for a reappraisal.
    Vanfleteren L; Fabbri LM; Papi A; Petruzzelli S; Celli B
    Int J Chron Obstruct Pulmon Dis; 2018; 13():3971-3981. PubMed ID: 30587953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Triple Inhaler versus Dual Bronchodilator Therapy in COPD: Real-World Effectiveness on Mortality.
    Suissa S; Dell'Aniello S; Ernst P
    COPD; 2022 Dec; 19(1):1-9. PubMed ID: 34544314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Open-inhaler versus single-inhaler triple therapy (long-acting muscarinic antagonist, inhaled corticosteroid, and long-acting β
    Wechsler ME; Oppenheimer JJ
    J Asthma; 2023 Sep; 60(9):1633-1645. PubMed ID: 36964764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative Effectiveness and Safety of Different Types of Inhaled Long-Acting β
    Wang MT; Lai JH; Huang YL; Liou JT; Cheng SH; Lin CW; Pan HY; Hsu YJ; Tsai CL
    Chest; 2021 Oct; 160(4):1255-1270. PubMed ID: 34023320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparisons of Efficacy and Safety between Triple (Inhaled Corticosteroid/Long-Acting Muscarinic Antagonist/Long-Acting Beta-Agonist) Therapies in Chronic Obstructive Pulmonary Disease: Systematic Review and Bayesian Network Meta-Analysis.
    Lee HW; Kim HJ; Jang EJ; Lee CH
    Respiration; 2021; 100(7):631-643. PubMed ID: 33971649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Escalation Time to Open Triple Combination Therapy from the Initiation of LAMA versus ICS/LABA in COPD Management: Findings from Comparing the Incidence of Tiotropium and ICS/LABA in Real-World Use in South Korea (CITRUS) Study.
    Lee YJ; Rhee CK; Hwang YI; Yoo KH; Lee SE; Lee D; Park YB; Kim Y
    J Pers Med; 2021 Dec; 11(12):. PubMed ID: 34945797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of Long-Acting Muscarinic Antagonist/Long-Acting β
    Petite SE
    Ann Pharmacother; 2017 Aug; 51(8):696-705. PubMed ID: 28410560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.